Sign up to save your podcasts
Or
Share Ep. 162 - New CMS Payment Models, China Markets Outlook, & Zhang's Latest Start-Up
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Ep. 162 - New CMS Payment Models, China Markets Outlook, & Zhang's Latest Start-Up
On the latest BioCentury This Week podcast, BioCentury’s editors discuss what the latest payment models from CMS could mean for cell and gene therapies, and how a new model could incentivize the completion of confirmatory trials for drugs with accelerated approval. BioCentury's editors also discuss the outlook for China's public markets and details around the genetic medicine delivery technology of recently launched Aera Therapeutics.
Reach us by sending a text
View all episodes
By BioCentury
4.8
3131 ratings
On the latest BioCentury This Week podcast, BioCentury’s editors discuss what the latest payment models from CMS could mean for cell and gene therapies, and how a new model could incentivize the completion of confirmatory trials for drugs with accelerated approval. BioCentury's editors also discuss the outlook for China's public markets and details around the genetic medicine delivery technology of recently launched Aera Therapeutics.
Reach us by sending a text
More shows like BioCentury This Week
View all
Exchanges
960 Listeners
WSJ What’s News
4,338 Listeners
Bloomberg Intelligence
400 Listeners
Odd Lots
1,929 Listeners
Bloomberg Businessweek
421 Listeners
The Readout Loud
322 Listeners
The Journal.
6,087 Listeners
Biotech 2050 Podcast
62 Listeners
All-In with Chamath, Jason, Sacks & Friedberg
9,938 Listeners
Business Of Biotech
86 Listeners
Biotech Hangout
18 Listeners
The Markets
79 Listeners
Ground Truths
50 Listeners
The Top Line
13 Listeners
The BioCentury Show
12 Listeners